Certara (CERT) Stock Price
Certara Price
Over the last 7 years Certara grew revenue by 16.6% annually, reaching 399.10 M USD. For Certara, the net margin of -0.4% is up versus -4.9% a few years ago. The consensus 12-month price target for Certara is 8.00 USD, about 12.2% below where the stock trades today. Of 19 analysts, 10 rate the stock a buy — an overall Buy consensus. The stock trades about 103% above its 52-week low.
Certara stock price
Certara Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 163.00 | 208.00 | 243.00 | 286.00 | 335.00 | 354.00 | 385.00 | 418.00 | 380.00 | 389.00 | 413.00 | 440.00 |
| – | 27.61 | 16.83 | 17.70 | 17.13 | 5.67 | 8.76 | 8.57 | -9.09 | 2.37 | 6.17 | 6.54 |
| 56.44 | 61.54 | 58.44 | 60.84 | 60.60 | 60.17 | 59.74 | 61.48 | 61.48 | 61.48 | 61.48 | 61.48 |
| 92.00 | 128.00 | 142.00 | 174.00 | 203.00 | 213.00 | 230.00 | 257.00 | 233.64 | 239.17 | 253.93 | 270.53 |
| -4.00 | 19.00 | -24.00 | 13.00 | 32.00 | -32.00 | -1.00 | 27.00 | 98.00 | 108.00 | 119.00 | 138.00 |
| -2.45 | 9.13 | -9.88 | 4.55 | 9.55 | -9.04 | -0.26 | 6.46 | 25.79 | 27.76 | 28.81 | 31.36 |
| -33.00 | -8.00 | -49.00 | -13.00 | 14.00 | -55.00 | -12.00 | -1.00 | 54.00 | 62.00 | 69.00 | 80.00 |
| – | -75.76 | 512.50 | -73.47 | -207.69 | -492.86 | -78.18 | -91.67 | -5,500.00 | 14.81 | 11.29 | 15.94 |
| 132.00 | 147.16 | 135.75 | 155.62 | 159.24 | 159.43 | 161.27 | 160.39 | 160.39 | 160.39 | 160.39 | 160.39 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Certara generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Certara retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Certara's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Certara has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Certara's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Certara business model & stock analysis
Certara SWOT Analysis
Strengths
Certara Inc has a strong reputation in the pharmaceutical industry due to its advanced technology and expertise in pharmacokinetic modeling and simulation.
The company offers a comprehensive range of software solutions and consulting services, which enables it to provide tailored solutions to pharmaceutical companies.
Certara Inc has a well-established customer base, including top pharmaceutical companies and regulatory agencies, which provides a stable source of revenue.
Weaknesses
Certara Inc relies heavily on the pharmaceutical industry, which is subject to market fluctuations and regulatory changes. These factors can impact the company's financial performance.
The company faces intense competition from other technology and consulting firms in the pharmaceutical industry, which could potentially affect its market share.
Opportunities
As pharmaceutical companies continue to focus on drug development and regulatory approval, there is an increasing demand for Certara's services and software solutions.
The incorporation of artificial intelligence and machine learning in pharmacokinetic modeling presents an opportunity for Certara Inc to further enhance its offerings and gain a competitive edge.
Threats
Changes in government regulations and industry standards can pose a threat to Certara Inc's business operations and may require the company to adapt its services accordingly.
The emergence of new competitors in the pharmaceutical technology and consulting space could potentially erode Certara Inc's market share and impact its revenue growth.
Certara Eulerpool Fair Value
Certara historical P/E ratio, EBIT multiple, and P/S ratio
Current Certara forecasts and price targets in September 2026
Analyst Price Targets 2026Certara Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 8/5/2026 | Maintained | Equal Weight | 62 | |
| 5/12/2026 | Maintained | Overweight | 64 | |
| 5/12/2026 | Maintained | Equal Weight | 46 | |
| 5/12/2026 | Maintained | Hold | – | |
| 5/12/2026 | Maintained | Market Perform | 74 | |
| 5/12/2026 | Maintained | Equal Weight | 62 | |
| 5/12/2026 | Maintained | Neutral | 65 | |
| 4/13/2026 | Maintained | Overweight | 40 | |
| 3/6/2026 | Downgrade | OverweightEqual Weight | 62 | |
| 2/27/2026 | Maintained | Overweight | 62 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Certara Earnings Calls
Certara Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/5/2026 | 0.09USD | - | 92.75 MUSD | - | 2026 Q3 |
| 8/4/2026 | 0.09USD | 0.08USD | 98.09 MUSD | - | 2026 Q2 |
| 5/11/2026 | 0.11USD | 0.09USD | 106.13 MUSD | - | 2026 Q1 |
| 2/26/2026 | 0.11USD | 0.09USD | 103.07 MUSD | - | 2025 Q4 |
| 11/6/2025 | 0.11USD | 0.14USD | 103.23 MUSD | - | 2025 Q3 |
| 8/6/2025 | 0.10USD | 0.07USD | 104.08 MUSD | - | 2025 Q2 |
| 5/5/2025 | 0.13USD | 0.14USD | 104.27 MUSD | - | 2025 Q1 |
| 2/26/2025 | 0.13USD | 0.15USD | 99.13 MUSD | - | 2024 Q4 |
| 11/6/2024 | 0.11USD | 0.13USD | 98.26 MUSD | - | 2024 Q3 |
| 8/6/2024 | 0.11USD | 0.07USD | 96.05 MUSD | - | 2024 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Certara stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Certara shareholder structure
| % | Name |
|---|---|
8.98341% | |
5.37610% | |
4.90275% | |
4.30603% | |
3.74785% | |
3.36562% |
Certara Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
23.50% | SEC ↗ | |
23.50% | SEC ↗ | |
23.50% | SEC ↗ | |
22.80% | SEC ↗ | |
22.60% | SEC ↗ | |
18.60% | SEC ↗ | |
18.60% | SEC ↗ | |
11.00% | SEC ↗ | |
8.70% | SEC ↗ | |
6.90% | SEC ↗ |
Certara Executives and Management Board
16 members · avg. age 62 · 25 % women
Dr. William Feehery (55)
Chief Executive Officer, Director · since 2019
7.22 M USD
Management
Mr. John Gallagher (52)
Chief Financial Officer, Senior Vice President
Mr. Leif Pedersen (61)
President, Chief Commercial Officer
Dr. Robert Aspbury (53)
President - Certara Predictive Technologies
Mr. Adrian Mckemey (61)
President - Certara Drug Development Solutions
Ms. Rona Anhalt (60)
Chief Human Resources Officer
Mr. Daniel Corcoran (58)
Senior Vice President, General Counsel
Board of Directors
Mr. James Cashman (71)
Independent Chairman of the Board
Mr. Eran Broshy (66)
Independent Director
Ms. Nancy Killefer (71)
Independent Director
Mr. Matthew Walsh (58)
Independent Director
Ms. Cynthia Collins (66)
Independent Director
Ms. Rosemary Crane (65)
Independent Director
Frequently asked questions about Certara
The main competitors of Certara Inc in the market include industry leaders such as Simulations Plus, Inc. and Schrödinger, Inc.
Certara Inc operates with a business model focused on providing solutions and services to support the entire drug development process. As a leading provider of biosimulation software and technology, Certara integrates quantitative methods and software applications to help pharmaceutical and biotechnology companies optimize development and improve drug safety. With a strong focus on precision medicine and personalized therapies, Certara combines scientific expertise with advanced technology to facilitate decision-making in clinical and regulatory activities. Their comprehensive suite of tools and services enables clients to streamline drug development, predict drug outcomes, and ultimately bring safer and more effective medicines to market efficiently.
Certara Inc is primarily active in the pharmaceutical and biotechnology industries.
Certara Inc is a leading provider of model-informed drug development and regulatory science solutions. Founded in 2008, Certara has constantly evolved and grown, becoming a trusted partner to more than 1,500 biopharmaceutical companies and academic institutions. Certara's innovative software and services help improve the efficiency and success of drug development, reducing costs and timeframes. With a team of highly experienced scientists and industry experts, Certara combines cutting-edge technology with deep domain knowledge to facilitate informed decision-making throughout the drug development process. Certara's commitment to excellence has enabled it to establish a strong presence globally, making it a highly respected and influential player in the pharmaceutical industry.
Certara Inc has achieved several significant milestones throughout its history. Some noteworthy achievements include the acquisition of Simcyp Limited, a leading provider of physiologically-based pharmacokinetic modeling and simulation services. This acquisition has strengthened Certara's position as a global leader in modeling and simulation software and has expanded its reach in the pharmaceutical industry. Additionally, Certara has collaborated with key industry stakeholders to develop innovative solutions for drug development and optimization, further contributing to its reputation as a trusted partner in pharmaceutical sciences. The company's commitment to research, technological advancements, and strategic partnerships has propelled Certara Inc towards continuous growth and success.
Certara Inc is primarily present in multiple countries and regions around the world. With a global presence, the company operates in North America, Europe, Asia-Pacific, and Latin America. It has established offices and collaborations in various key pharmaceutical and biotechnology hubs, including the United States, United Kingdom, Germany, France, Japan, China, and Brazil. Certara's extensive international reach allows it to serve a diverse clientele and partner with industry leaders across different geographical locations, further strengthening its position as a leading provider of scientific software and services in the life sciences industry.
Certara Inc represents a strong commitment to scientific excellence and innovation, striving to bridge the gap between discovery and application. The company values collaborative partnerships, with a focus on providing cutting-edge solutions to support informed decision-making in drug development and regulatory processes. Certara fosters a culture of integrity and transparency, aiming to deliver value to its clients and stakeholders while improving patient outcomes. With its advanced technology platforms and expert-driven approaches, Certara empowers researchers and drug developers to optimize drug discovery and development, ensuring safer and more effective therapies for patients worldwide.
Analysts currently set an average price target of 8.50 USD for the Certara stock (median: 8.00 USD), implying -6.7 % versus the latest price. The consensus is based on 19 analyst ratings.
19 analysts currently rate the Certara stock: 10 recommend buying, 9 holding and 0 selling. For 2026, analysts expect Certara to generate revenue of 380.10 M USD and earnings per share of 0.34 USD.
Converted at the current exchange rate, the Certara share trades at 7.99 EUR (9.11 USD).
The Certara share (CERT) is listed on 2 stock exchanges, including: NASDAQ (CERT), Hamburg (700.HM).
Certara Inc is a leading company in the field of biosimulation and technology platforms for drug development. The company offers a wide range of products and services to support its customers in developing, testing, and bringing safer and more effective drugs to market. Certara's business model includes three main divisions: Modelling & Simulation, Regulatory Science, and Clinical Pharmacology. Each of these divisions offers specialized services and products to meet the needs of different customers in the healthcare industry. Modelling & Simulation is an important division of Certara, based on the application of biosimulation and modeling techniques to support drug research and development activities. This division specializes in providing knowledge in modeling and simulation methods and developing software products to help evaluate and optimize the effectiveness and safety of drugs. The Regulatory Science division is focused on promoting collaborations with regulatory authorities in the evaluation of drug products. This division works with pharmaceutical companies and authorities to ensure that drug products meet all necessary regulatory requirements and that their safety and efficacy are ensured during clinical trials and use. Certara's Clinical Pharmacology division specializes in developing strategies to optimize the clinical effectiveness of drugs through clinical pharmacology and bioanalysis phases. Additionally, this division also develops behavioral diagnostic tools and innovative technologies to optimize drug selection and patient treatment. Certara also offers a variety of products tailored to customer needs, including simulation tools, analysis tools, databases, and software packages for drug development. Some of the most commonly used products are the D360 platform and the physiology platform (PK/PD modeling), which specifically focus on analyzing and modeling drug effects in the body. Overall, Certara's business model is designed to offer customers a comprehensive range of services and products to support drug development. By combining modeling and simulation strategies, regulatory science methods, and clinical pharmacology, the company provides its customers with a unique solution for optimizing drug development. With its portfolio of innovative products and services, Certara is a leader in the industry and sets the standard for the future of drug development.
The expected revenue of Certara is 380.10 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Certara is 54.44 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Certara is currently 26.84. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Certara stock.
The price-to-sales ratio (P/S) of Certara is currently 3.84. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Certara stock.
The Eulerpool Quality Score for Certara is 2/10.
The ISIN of Certara is US15687V1098. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Certara is A2QJL8. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Certara is CERT. The ticker symbol is used to trade Certara shares on the stock exchange.
Certara paid dividends every year for the past 0 years.
Certara is assigned to the 'Health' sector.
The dividends of Certara are distributed in USD.
Certara stock
Certara Peer Group
Certara Ticker
Certara FIGI
All fundamentals and in-depth analysis of Certara
Our stock analysis for Certara stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Certara. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.